“If you're doing diligence and you're not using Derisq, I'm not sure what you're doing.” — Industry leaders promote predictive risk analysis with AI at GATC Health and Bioneex webinar

“Derisking Biotech Investments with Predictive AI Analysis”

Date: October 17, 2025
Hosted by: GATC Health and Bioneex
Moderator: Dr. Rahul Gupta, President, GATC Health

Finance, regulatory, and policy leaders converged for a webinar hosted by GATC Health and Bioneex, “Derisking Biotech Investments with Predictive AI Analysis.” The discussion focused on how artificial intelligence is revolutionizing drug discovery, risk prediction, and investor decision-making across the biopharma sector.

Link to Entire Webinar

Key Quotes

“Imagine a world where AI can fundamentally change the drug discovery value chain from what is essentially a closed-loop venture capital or power law business, where one in ten returns results at all, to basically a business that is working capital, where nine out of ten returns value. We dramatically increase the velocity of drugs and therapies available to all of us.”
— Greg Sarafin, CEO of Sarafin Advisory, former Global Vice Chair – Alliances and Ecosystems at Ernst & Young

“Nowadays AI is everywhere, and FDA is no exception.”
— Gurpreet K. Gill-Sangha, Ph.D., former Supervisor, Office of Pharmaceutical Quality, Center of Drug Evaluation and Research, FDA

“The question is whether you're using [AI] today or not. And if you don't use it, then probably you will not be in the market tomorrow.”
— Dr. Smbat Rafayelyan, CEO, Bioneex; former Regulatory Affairs Manager, Pfizer

“AI's influence in biotech is not just a passing trend. It's driving smarter due diligence. It's causing more accurate risk assessments and stronger investment outcomes across the board.”
— Dr. Rahul Gupta, President, GATC Health; former Director, White House Office of National Drug Control Policy

“You're going to see the investment community become more aggressive because there's less risk, more confidence [with the Derisq AI report], and you're going to see the biotech community being more efficient as far as capital expenditure. And that will lead to more medicines in the pipeline.”
— Tyrone Lam, Chief Business Officer, GATC Health

Discussion Highlights

The panel examined:

• The role of AI in reshaping the regulatory environment

• Private sector adoption of predictive analytics

• How Derisq™ AI empowers investors with data-driven insights to evaluate biotech opportunities

Attendees gained real-world examples and actionable strategies for navigating an increasingly data-driven biotech landscape.

Watch the Entire Webinar →
(Insert actual webinar link here)

Disclaimer

During the October 17th, 2025 webinar, “Derisking Biotech Investments with Predictive AI Analysis,” GATC Health Chief Business Officer V. Tyrone Lam misstated a figure.
Correction: The correct amount is nearly 400 trillion data points, not four trillion as stated. GATC Health regrets the error.

About GATC Health

GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body—achieving 91% specificity and 86% sensitivity.

Trusted by global insurance, biopharma, and investment leaders, GATC Health’s flagship product, the Derisq™ AI report, assesses and predicts drug candidate safety, efficacy, and potential side effects before development capital is committed.

The company’s AI platform is generative, capable of creating intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces late-stage failures to deliver safer, more effective therapies worldwide.

🔗 www.gatchealth.com
📞 (833) 333-4323
📧 info@gatchealth.com